{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:31:38Z","timestamp":1768530698145,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s41669-025-00610-1","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:37:06Z","timestamp":1762551426000},"page":"153-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis"],"prefix":"10.1007","volume":"10","author":[{"given":"Gijs","family":"van de Wetering","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Paul","family":"Roc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lytske","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gargi","family":"Ratnaparkhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-3465","authenticated-orcid":false,"given":"Beenish S.","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"610_CR1","unstructured":"Mayo clinic: Chronic Lymphocytic Leukemia. 2024. https:\/\/www.mayoclinic.org\/diseases-conditions\/chronic-lymphocytic-leukemia\/symptoms-causes\/syc-20352428."},{"key":"610_CR2","unstructured":"Canadian Cancer Society. Chronic lymphocytic leukemia statistics. 2024."},{"key":"610_CR3","unstructured":"Owen C (lead) PA, Puckrin R, Shafey M, Tilley D. Clinical Practice Guideline on [CLL, Version 10]. Cancer Care Alberta, Alberta Health Services; 2022."},{"issue":"4","key":"610_CR4","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/curroncol29040223","volume":"29","author":"R Garaszczuk","year":"2022","unstructured":"Garaszczuk R, Yong JHE, Sun Z, de Oliveira C. The economic burden of cancer in Canada from a societal perspective. Curr Oncol. 2022;29(4):2735\u201348.","journal-title":"Curr Oncol"},{"key":"610_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107016","volume":"125","author":"C Owen","year":"2023","unstructured":"Owen C, Banerji V, Johnson N, Gerrie A, Aw A, Chen C, et al. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leuk Res. 2023;125:107016.","journal-title":"Leuk Res"},{"key":"610_CR6","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH Reimbursement Recommendation: Ibrutinib (Imbruvica). Ottawa (ON); 2023."},{"key":"610_CR7","unstructured":"Canada Drug Agency. Provisional Funding Algorithm Chronic lymphocytic leukemia. 2025."},{"key":"610_CR8","unstructured":"Canada\u2019s Drug Agency (CDA-AMC). CDA-AMC Reimbursement Recommendation: Venetoclax (Venclexta). Ottawa (ON); 2024."},{"issue":"19","key":"610_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, Furstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388(19):1739\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"610_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40258-019-00513-3","volume":"17","author":"A Bullement","year":"2019","unstructured":"Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy. 2019;17(6):771\u201380.","journal-title":"Appl Health Econ Health Policy"},{"key":"610_CR11","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Canadian Agency for Drugs and Technologies in Health (CADTH) DRUG REIMBURSEMENT REVIEW: Pharmacoeconomic Report\u2014Venetoclax (VENCLEXTA). 2020."},{"key":"610_CR12","unstructured":"Woods B SE, Palmer S, Latimer N, Soares M. Document 19. Partitioned survival analysis for decision modelling in health care: a critical review. 2017."},{"key":"610_CR13","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Venetoclax and Obinutuzumab for Chronic Lymphocytic Leukaemia: Final Clinical Guidance Report. 2020 November 17, 2020."},{"key":"610_CR14","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. Ottawa; 2017."},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"610_CR16","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v070.i08","author":"CH Jackson","year":"2016","unstructured":"Jackson CH. Flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016. https:\/\/doi.org\/10.18637\/jss.v070.i08.","journal-title":"J Stat Softw"},{"key":"610_CR17","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2023."},{"issue":"1","key":"610_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333.","journal-title":"Ann Oncol"},{"key":"610_CR19","unstructured":"Phillippo DM. multinma: Bayesian Network Meta-Analysis of Individual and Aggregate Data. R package version 0.7.1. 2024."},{"key":"610_CR20","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: NICE Decision Support Unit Technical Support Documents; 2014."},{"key":"610_CR21","unstructured":"Hancock S WB, Hyde C. Fludarabine as first line therapy for chronic lymphocytic leukaemia: a west midlands health technology assessment collaboration report. 2002."},{"key":"610_CR22","unstructured":"National Institute for Health and Care Excellence. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174). 2009."},{"issue":"6","key":"610_CR23","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.1503\/cmaj.170317","volume":"190","author":"JR Guertin","year":"2018","unstructured":"Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on the 2013\u20132014 Canadian community health survey. CMAJ. 2018;190(6):E155\u201361.","journal-title":"CMAJ"},{"key":"610_CR24","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Canadian Agency for Drugs and Technologies in Health (CADTH) Reimbursement Review: Zanubrutinib (Brukinsa). Combined Clinical and Pharmacoeconomic Review Report.; 2023."},{"key":"610_CR25","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Canadian Agency for Drugs and Technologies in Health (CADTH) Reimbursement Review: Ibrutinib (Imbruvica). Combined clinical and pharmacoeconomic review report. 2024."},{"key":"610_CR26","unstructured":"Ontario Drug Benefit Formulary\/Comparative Drug Index [Internet]. 2024. https:\/\/www.formulary.health.gov.on.ca\/formulary\/."},{"key":"610_CR27","unstructured":"Exceptional Access Program product prices. [Internet]. 2024. https:\/\/www.ontario.ca\/page\/exceptional-access-program-product-prices."},{"key":"610_CR28","unstructured":"Janssen Inc. PrIMBRUVICA\u00ae (ibrutinib) product monograph. 2023. https:\/\/pdf.hres.ca\/dpd_pm\/00070123.PDF."},{"key":"610_CR29","unstructured":"AbbVie Corporation. PrVENCLEXTA\u00ae (venetoclax tablets) product monograph. 2022. https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/products\/VENCLEXTA_PM_EN.pdf."},{"key":"610_CR30","unstructured":"AstraZeneca Canada Inc. CALQUENCE\u00ae (acalabrutinib tablets) product monograph. https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/calquence-product-monograph-en.pdf."},{"key":"610_CR31","unstructured":"BeiGene Switzerland GmbH. Pr BRUKINSA\u00ae (zanubrutinib capsules) product monograph. 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00064798.PDF."},{"key":"610_CR32","unstructured":"Cancer Care Ontario. FC+R Regimen (Fludarabine-Cyclophosphamide-Rituximab). https:\/\/www.cancercareontario.ca\/en\/system\/files_force\/FCR_HEM_CLL.pdf?download=1."},{"key":"610_CR33","unstructured":"Sehn LH GA. BC Cancer Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and riTUXimab. http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Lymphoma-Myeloma\/LYCLLFBR_Protocol.pdf."},{"issue":"2","key":"610_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s41669-022-00375-x","volume":"7","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee A, van de Wetering G, Goeree R, Owen C, Desbois AM, Barakat S, et al. A probabilistic cost-effectiveness analysis of venetoclax and obinutuzumab as a first-line therapy in chronic lymphocytic leukemia in Canada. Pharmacoeconomics. 2023;7(2):199\u2013216.","journal-title":"Pharmacoeconomics"},{"key":"610_CR35","unstructured":"Ontario Ministry of Health. Schedule of Benefits: Physician Services Under the Health Insurance Act (February 20, 2024). 2024."},{"key":"610_CR36","unstructured":"Government of Canada Job Bank. Wages for Registered nurses and registered psychiatric nurses. 2024."},{"key":"610_CR37","unstructured":"National Institute for Health and Care Excellence. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891). 2023."},{"key":"610_CR38","unstructured":"Ontario Ministry of Health. Schedule of Benefits for Laboratory Services. 2023."},{"key":"610_CR39","unstructured":"Canadian Institute for Health Information (CIHI). Canadian Institute for Health Information (CIHI). Patient Cost Estimator. 2022. https:\/\/www.cihi.ca\/en\/patient-cost-estimator."},{"key":"610_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e18840","author":"J Truong","year":"2022","unstructured":"Truong J, Cheung M, Seung S-J, Dharma C, Cheng SY, Earle C, et al. Phase-specific costs of care in diffuse large B-cell lymphoma in Ontario, Canada. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e18840.","journal-title":"J Clin Oncol"},{"key":"610_CR41","unstructured":"Canadian Institute for Health Information (CIHI). Canadian Institute for Health Information (CIHI): Hospital spending: focus on the emergency department. 2020."},{"key":"610_CR42","unstructured":"National Institute for Health and Care Excellence. Venetoclax for treating chronic lymphocytic leukaemia( TA796). 2022."},{"issue":"26","key":"610_CR43","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"610_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000336","volume":"4","author":"N Kutsch","year":"2020","unstructured":"Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, et al. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). Hemasphere. 2020;4(1):e336.","journal-title":"Hemasphere"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00610-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:16:30Z","timestamp":1768472190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00610-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00610-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.G., N.P.R., S.B., and B.S.M. are employees of AbbVie. Employees of AbbVie may hold equity. S.K. is an employee of PIVINA and C.V. is the managing director of PIVINA Consulting Inc., a company that has served as a consultant to AbbVie and has received research funding from AbbVie. G.W., L.B. and G.R. are employees of OPEN Health, which served as a consultant to AbbVie and has received research funding from AbbVie. C.O. has received research funding from AbbVie, Roche, AstraZeneca, Janssen, Beigene, and Merck and has served as a consultant to AbbVie, Astrazeneca, Beigene, Janssen, Roche, and Merck. V.B. has received research funding from CIHR, CancerCare Manitoba, University of Manitoba, AstraZeneca, and Eli Lilly. V.B. has contracts with Beigene, AbbVie, and Janssen related to the CLL Unit, and has served as a consultant to AbbVie, Janssen, AstraZeneca, Merck, Eli Lilly, and Beigene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data reported in this manuscript are available within the article and its supplementary materials. Additional data may be requested by contacting AbbVie.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Code may be requested by contacting AbbVie.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. AbbVie, OPEN Health, and PIVINA Consulting Inc. participated in the design, study conduct, analysis and interpretation of data, as well as the writing, review, and approval of the manuscript. C.O. and V.B. were involved in study conception and design, data interpretation and revision of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}